Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
   
Ask the Experts About

Facial WastingFacial Wasting
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


can i start regimen
Nov 10, 2008

1, My CD4 count is 143. I am afraid of taking ART keeping in mind it's side effects. Are there any medicines which will have less side effects. If I take ART later, what are the risks I have to face

Response from Dr. Pierone

The most commonly used HIV cocktail for patients newly starting treatment is Atripla. This agent is a three in one combination that contains tenofovir (Viread), emtricitabine (Emtriva), and efavirenz (Sustiva). This is the most popular agent mainly because it has fewer side effects than the other choices.

The risk of waiting is greater risk of illness and death. At your level of CD4+ lymphocyte count, the risks associated with waiting far outweigh the risks of treatment so I urge you to overcome your fears and get on therapy.

Good luck!



Previous
Distressed & confused
Next
forehead is getting bigger

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement